Alexion Pharmaceuticals Global Headquarters, New Haven, United States of America
Alexion Pharmaceuticals started construction on its new global headquarters in June 2013, located at 100 College Street, New Haven, Connecticut, US.
The new headquarters includes a sophisticated laboratory and an office building. It was opened in February 2016. Construction was sponsored by the city of New Haven, the State of Connecticut, and the US Department of Transportation.
The new building will provide employment for 200 to 300 people by 2017.
Details of Alexion's new headquarters
Alexion's new headquarters is located on a 12-storey building with a total floor space of around 500,000ft².
It includes a separate parking garage with 600 to 800 spaces. Existing 400 employees at the old facility in Connecticut were transferred to the new headquarters.
The new laboratory at the headquarters is used for developing life-transforming therapies for patients with severe and life-threatening disorders.
Construction of Alexion's new global headquarters
In June 2013, construction began with a ground-breaking ceremony, attended by New Haven mayor John DeStefano, Connecticut governor Dan Malloy and other dignitaries of Alexion Pharmaceuticals.
Contractors involved with Alexion's corporate facility
Winstanley Enterprises was awarded a $100m development contract in June 2013. The scope of the contract included construction of new laboratory and office building for Alexion to accommodate its new headquarters. It also involved the refurbishment of the College Street Bridge, pedestrian and bike improvements, as well as access to the neighbouring Air Rights garage.
Financing for Alexion's new global headquarters
The total expected investment for the construction of the new headquarters is $140m. The Connecticut state government contributes $51m for the project under its Department of Economic and Community Development (DECD) First Five programme.
The assistance is provided as a ten-year loan of $20m at 1% interest for five years. It also includes around $25m towards industrial sites reinvestment tax credits, and a $6m grant for the laboratory construction and equipment.
Between $16m and $20m are rebated under loan forgiveness schemes if the promised 200 to 300 permanent jobs are created.
Sustainability features of Alexion's new global HQ
The new headquarters building was constructed using eco-friendly methods. It is designed to obtain the LEED Silver environmental standard certification.
Alexion Pharmaceuticals is a leading international biopharmaceutical company currently headquartered at Cheshire, US. The company is engaged in innovation, development and commercialisation of life-transforming therapeutic products for severe and ultra-rare disorders. It employs around 1,700 people across 50 countries worldwide.
Alexion operates a manufacturing facility located in Rhode Island, and offers the product services to the patients in 50 countries.
Alexion's therapeutic products portfolio includes sole marketing drug Soliris (eculizumab), which is approved by both the US Food and Drug Administration (FDA) and the European Medical Agency (EMA) for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) indications.